Despite the known short- and long-term adverse outcomes related to glucocorticoid use, patients with SLE are still taking moderate-to-high daily doses of steroids. Fortunately, two biologic therapies aimed at different therapeutic targets in the type I interferon pathway and with better safety profiles than glucocorticoids are currently available for use. In this Hot Topics video, an expert rheumatologist will provide focused education on where currently available biologic therapies target the pathways involved in the pathogenesis of SLE and how this can relate to improved patient outcomes.
View this program in its entirety: www.exchangecme.com/groups/SL...
SLE Clinical Resource Center
www.exchangecme.com/SLEHotTop...
ExchangeCME.com is an online community of more than 48,000 active healthcare professionals who have access to a variety of enduring educational activities and other disease state-focused resources. The Website’s core mission is to support patient-centered care via education that is tailored to the needs of various clinician audiences.
By consolidating evidence-based resources and hosting only accredited educational programs without any promotional content or advertising, ExchangeCME.com serves as an independent, trusted, and balanced source of free CME/CE for physicians, nurses, pharmacists, and other healthcare providers.
Follow us on socials!
Twitter: / exchangecme
Facebook: / exchangecme
Linkedin: / 10863550
#lupus #lupusawarenessmonth #lupuswarrior #systemiclupuserythematosus